Price competition to hit oncology next: BioPharma Dive's 2018 predictions

Cancer drugs routinely command a premium price. A crowded pipeline of me-too rivals could change that. 

By Ned Pagliarulo • Jan. 10, 2018

JPM18: Allergan says no Restasis generic before second quarter

Allergan has fought hard against generic competitors to its blockbuster eye drug.

By Suzanne Elvidge • Jan. 10, 2018

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Azar talks list prices, mandatory Medicare pilots

The HHS nominee identified high drug prices and shifting payment models to reward health outcomes as top priorities.

By David Lim • Jan. 9, 2018

FDA rejects Allergan's latest bid to block Restasis copies

Allergan could face generic competition to Restasis as soon as this year, bringing with it a potential blow to the company's bottom line.

By Ned Pagliarulo • Jan. 5, 2018

Drug approvals surged in 2017. What does that mean for pharma?

The FDA approved more novel medicines in 2017 than in any year since 1996.

By Ned Pagliarulo • Jan. 3, 2018

Big drugmakers ring in new year with price hikes

Allergan, Amgen and Biogen are just a few of the companies charging more for their meds in 2018.

By Jacob Bell • Jan. 3, 2018

Spark sets precedent with outcomes models, $850K gene therapy price tag

After winning approval of Luxturna in December, the biotech revealed the blindness treatment's cost, along with plans for outcomes-based rebate contracts.

By Lisa LaMotta • Jan. 3, 2018

Allergan to cut 1,000 jobs as generic competition threatens

The big question for 2018 is whether copies of Allergan's eye drug Restasis will enter the market. But the pharma also faces loss of exclusivity for several other products.

By Ned Pagliarulo • Jan. 3, 2018

Inovio reworks immunotherapy deal with eye to China

Under an amended agreement, ApolloBio will pay $23 million upfront for exclusive rights within Greater China for Inovio's HPV immunotherapy. 

By Suzanne Elvidge • Jan. 3, 2018

Galapagos' progress won't rattle CF markets, analysts say

Pipeline progress, including positive Phase 2 data, didn't sway some analyst beliefs that Vertex will continue to dominate the cystic fibrosis market.

By Jacob Bell • Jan. 3, 2018

Top 10 stories that had pharma execs talking

From CAR-T to potential deals, BioPharma readers dove into these pieces.

By Lisa LaMotta • Jan. 3, 2018

FDA drops boxed warning for combo asthma drugs

A review of four safety studies found pairing long-acting beta agonists and inhaled corticosteroids did not present a greater safety risk.

By Suzanne Elvidge • Dec. 22, 2017

Kymriah, Yescarta could be cost-effective, ICER finds

Despite steep prices for both CAR-T therapies, a draft report from the watchdog group suggested the clinical benefit they deliver could be worth the cost.

By Ned Pagliarulo • Dec. 21, 2017

Spending on prescription drugs has almost doubled since the '90s, report finds

About 12% of personal healthcare service spending in 2015 went toward prescription medicine sold at retail pharmacies, up from 7%. 

By Jacob Bell • Dec. 19, 2017

Hikma to sell Celltrion's Rituxan biosimilar in Africa, Middle East

The London-based generics company already markets in the MENA region two other copycat biologics developed by Celltrion.

By Lisa LaMotta • Dec. 19, 2017

Aerie eyes glaucoma market after early FDA win

Approval of Rhopressa could make Aerie a more attractive takeout option for ophthalmology-focused biopharmas. 

By Ned Pagliarulo • Dec. 19, 2017

Shire looks to stall Hemlibra impact with court injunction

Through a recently filed motion for injunction, Shire is requesting a federal court restrict Roche's ability to manufacture and sell its disruptor hemophilia drug.

By Jacob Bell • Dec. 18, 2017

Novartis buys regulatory fast pass for $130M

Ultragenyx sold the Swiss pharma a Priority Review Voucher it had received last month for the approval of its pediatric rare disease drug Mepsevii. 

By Ned Pagliarulo • Dec. 18, 2017

Positive news from the EMA for Herceptin biosimilar

Celltrion's Herzuma, its biosimilar of Roche's Herceptin, has snagged a positive opinion from the EMA, bringing the copycat drug a step closer to the market.

By Suzanne Elvidge • Dec. 17, 2017

FDA OK's new Remicade copycat but no launch planned

Pfizer has snagged a U.S. approval for Ixifi, its second Remicade biosimilar, but won't be taking it to market any time soon.

By Suzanne Elvidge • Dec. 15, 2017

Vertex licenses its first drug from CRISPR collaboration

CTX001 is a preclinical, ex vivo therapy that the biotechs are looking to push into Phase 1/2 testing for blood disorders in 2018.

By Jacob Bell • Dec. 13, 2017

After a decade of work, Otsuka and GW part ways on Sativex

A fizzled licensing agreement means GW will regain U.S. rights to its cannabinoid drug, which could be more of an albatross than a blessing.

By Jacob Bell • Dec. 13, 2017

Sanofi's Humalog follow-on gets FDA nod

With its diabetes unit on the decline, Sanofi is banking on a "more affordable" treatment to help prop up revenue.

By Jacob Bell • Dec. 12, 2017

Ardelyx signs a Chinese commercialization deal for GI drug

Fosun is continuing its mission to bring biotech to a Chinese domestic market.

By Suzanne Elvidge • Dec. 12, 2017

PwC: Opioids and Medicare pressures will challenge industry in 2018

BioPharma Dive Senior Editor Lisa LaMotta sat down with the US Pharma and Life Science Leader from PwC to discuss issues to watch in 2018. 

By Lisa LaMotta • Dec. 12, 2017